Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,929 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03394365 | A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy(ALLELE) | recruiting | Phase 3 | 115 | Pierre Fabre MedicamentINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT05405166 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM(IRAKLIA) | active not recruiting | Phase 3 | 531 | SanofiINDUSTRY |
| 21 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX) | recruiting | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 15 | Sep 2, 2026 | clinicaltrials |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | recruiting | Phase 3 | 448 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 18 | Sep 2, 2026 | clinicaltrials |
| NCT00553410 | Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer(SOLE) | completed | Phase 3 | 4,884 | ETOP IBCSG Partners FoundationNETWORK | 20 | Sep 1, 2026 | clinicaltrials |
| NCT02582697 | Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours(P3BEP) | recruiting | Phase 3 | 500 | University of SydneyOTHER | 4 | Sep 1, 2026 | clinicaltrials |
| NCT04008706 | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients(ASSURE) | completed | Phase 3 | 552 | AstraZenecaINDUSTRY | 17 | Sep 1, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT06799247 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | active not recruiting | Phase 3 | 128 | Cartesian TherapeuticsINDUSTRY | 8 | Sep 1, 2026 | clinicaltrials |
| NCT02305654 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)(InPACT) | active not recruiting | Phase 3 | 200 | Institute of Cancer Research, United KingdomOTHER | 2 | Aug 31, 2026 | clinicaltrials |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON) | active not recruiting | Phase 3 | 308 | Janssen Research & Development, LLCINDUSTRY | 26 | Aug 31, 2026 | clinicaltrials |
| NCT07768189 | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma(TEMPO-1) | not yet recruiting | Phase 3 | 260 | Corbus Pharmaceuticals Inc.INDUSTRY | 3 | Aug 31, 2026 | clinicaltrials |
| NCT04170283 | A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib | active not recruiting | Phase 3 | 955 | BeOne MedicinesINDUSTRY | 18 | Aug 28, 2026 | clinicaltrials |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | active not recruiting | Phase 3 | 405 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 28, 2026 | clinicaltrials |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC(PACIFIC-8) | active not recruiting | Phase 3 | 791 | AstraZenecaINDUSTRY | 28 | Aug 28, 2026 | clinicaltrials |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005) | active not recruiting | Phase 3 | 710 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Aug 28, 2026 | clinicaltrials |
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | active not recruiting | Phase 3 | 686 | Merck Sharp & Dohme LLCINDUSTRY | 32 | Aug 28, 2026 | clinicaltrials |
| NCT05338970 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | active not recruiting | Phase 3 | 586 | Daiichi SankyoINDUSTRY | 21 | Aug 27, 2026 | clinicaltrials |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma(CERVINO) | active not recruiting | Phase 3 | 421 | AbbVieINDUSTRY | 25 | Aug 27, 2026 | clinicaltrials |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.(EMPHASIS) | completed | Phase 3 | 81 | ETOP IBCSG Partners FoundationNETWORK | 12 | Aug 26, 2026 | clinicaltrials |
| NCT02477696 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 533 | Acerta Pharma BVINDUSTRY | 15 | Aug 26, 2026 | clinicaltrials |
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | completed | Phase 3 | 738 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT03875235 | Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)(TOPAZ-1) | active not recruiting | Phase 3 | 810 | AstraZenecaINDUSTRY | 17 | Aug 26, 2026 | clinicaltrials |
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 461 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi SankyoINDUSTRY | 26 | Aug 26, 2026 | clinicaltrials |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START) | active not recruiting | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT05625399 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma(RELATIVITY-127) | active not recruiting | Phase 3 | 579 | Bristol-Myers SquibbINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection(REZILIENT4) | active not recruiting | Phase 3 | 360 | Taiho Oncology, Inc.INDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT02475681 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL(ElevateTN) | active not recruiting | Phase 3 | 535 | Acerta Pharma BVINDUSTRY | 18 | Aug 25, 2026 | clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma(CheckMate 9DW) | completed | Phase 3 | 732 | Bristol-Myers SquibbINDUSTRY | 26 | Aug 25, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT02991482 | PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma(PROMISE-meso) | completed | Phase 3 | 144 | ETOP IBCSG Partners FoundationNETWORK | 3 | Aug 24, 2026 | clinicaltrials |
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER) | completed | Phase 3 | 701 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 24, 2026 | clinicaltrials |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments(MAGNETISMM-5) | recruiting | Phase 3 | 893 | PfizerINDUSTRY | 26 | Aug 24, 2026 | clinicaltrials |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | recruiting | Phase 3 | 1,600 | Summit TherapeuticsINDUSTRY | 17 | Aug 24, 2026 | clinicaltrials |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.(ADELA) | recruiting | Phase 3 | 300 | MedSIROTHER | 9 | Aug 24, 2026 | clinicaltrials |
| NCT02962414 | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | active not recruiting | Phase 3 | 206 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 21, 2026 | clinicaltrials |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | terminated | Phase 3 | 863 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 21, 2026 | clinicaltrials |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | recruiting | Phase 3 | 225 | TakedaINDUSTRY | 26 | Aug 21, 2026 | clinicaltrials |
| NCT03785964 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)(DeFi) | completed | Phase 3 | 142 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Aug 20, 2026 | clinicaltrials |
| NCT03971422 | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | completed | Phase 3 | 200 | UCB Biopharma SRLINDUSTRY | 17 | Aug 20, 2026 | clinicaltrials |
| NCT04008030 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW) | active not recruiting | Phase 3 | 839 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 20, 2026 | clinicaltrials |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | recruiting | Phase 3 | 1,300 | Kura Oncology, Inc.INDUSTRY | 16 | Aug 20, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials